NASDAQ:ANAB

Anaptysbio Stock Insider Trading

Healthcare > Biotechnology

Buy ANAB

*Your capital is at risk

$59.43

-0.560 (-0.93%)

At Close: Jun 23, 2026

AnaptysBio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -50.56. In total, the insiders bought 1.48M and sold 1.38M ANAB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-50.56
● Buy	1.48M shares
● Sell	1.38M shares
50% Buy Activity Strong Negative Correlation
Buy Signal Low Confidence Jan 06, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -50.56. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 15, 2026 Buy	Common Stock M-Exempt	Orwin John A Director	Director	6 030 Value: $358.8K
Jun 15, 2026 Buy	Restricted Stock Unit M-Exempt	Orwin John A Director	Director	6 030 Value: $358.8K
Jun 15, 2026 Buy	Restricted Stock Unit M-Exempt	Renton Hollings Director	Director	6 030 Value: $358.8K
Jun 15, 2026 Buy	Common Stock M-Exempt	Renton Hollings Director	Director	6 030 Value: $358.8K
Jun 15, 2026 Buy	Restricted Stock Unit M-Exempt	Schmid John P. Director	Director	6 030 Value: $358.8K
Jun 15, 2026 Buy	Common Stock M-Exempt	Schmid John P. Director	Director	6 030 Value: $358.8K
May 11, 2026 Buy	Common Stock J-Other	Hughes Owen Insider	Other	0 Value: $0
May 11, 2026 Buy	Restricted Stock Units A-Award	Hughes Owen Director	Director	11 250 Value: $764.1K
May 11, 2026 Buy	Common Stock J-Other	Murphy Christopher M. Insider	Other	0 Value: $0
May 11, 2026 Buy	Restricted Stock Units A-Award	Murphy Christopher M. Chief Financial Officer	C-Suite Officer	25 765 Value: $1.75M
Apr 27, 2026 Buy	Restricted Stock Unit A-Award	Gray Susannah Director	Director	11 250 Value: $749.1K
Apr 20, 2026 Sell	Employee Stock Option (right to buy) D-Return	Faga Daniel President, CEO	CEO / President	11 000 Value: $342.3K
Apr 20, 2026 Buy	Employee Stock Option (right to buy) A-Award	Faga Daniel President, CEO	CEO / President	133 400 Value: $4.29M
Apr 20, 2026 Sell	Employee Stock Option (right to buy) D-Return	Faga Daniel President, CEO	CEO / President	11 000 Value: $342.3K
Apr 20, 2026 Buy	Stock Option (right to buy) A-Award	Renton Hollings Director	Director	11 000 Value: $239.4K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	11 000 Value: $182.2K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	10 600 Value: $246.2K
Apr 20, 2026 Buy	Stock Option (right to buy) A-Award	Renton Hollings Director	Director	10 600 Value: $180.4K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	9 200 Value: $280.0K
Apr 20, 2026 Buy	Stock Option (right to buy) A-Award	Renton Hollings Director	Director	9 200 Value: $203.6K
Apr 20, 2026 Buy	Stock Option (right to buy) A-Award	Renton Hollings Director	Director	6 000 Value: $302.8K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	6 000 Value: $628.9K
Apr 20, 2026 Buy	Stock Option (right to buy) A-Award	Renton Hollings Director	Director	6 000 Value: $460.7K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	6 000 Value: $413.3K
Apr 20, 2026 Sell	Stock Option (right to buy) D-Return	Renton Hollings Director	Director	5 500 Value: $241.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ANAPTYSBIO INC

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...

Read Full Profile Here